Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.
BACKGROUND
Tumor lysis syndrome is a rare and potentially fatal complication of oncologic treatments, especially in solid tumors. To the best of our knowledge, tumor lysis syndrome has never been reported after trastuzumab and pertuzumab combination therapy. Knowledge of risk factors and active prevention proceedings is of utmost importance to avoid fatal outcomes.


METHODS
We present the case of a chemo-naive 58-year-old Belgian woman developing hypovolemic shock and multiple organ failure due to tumor lysis syndrome after a single dose of trastuzumab and pertuzumab in the context of the treatment of a metastatic breast cancer and resulting in fatal outcome despite optimal management.


CONCLUSIONS
Considering that targeted cancer therapies become increasingly effective, oncologists should be extremely cautious when treating patients at high risk of tumor lysis syndrome, even if they are not treated with cytotoxic chemotherapy, and determine appropriate prophylaxis.
Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium. celibaude@hotmail.com.|Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Université catholique de Louvain, 1200, Brussels, Belgium. celibaude@hotmail.com.
C
C
Baudon
Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium.|Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Université catholique de Louvain, 1200, Brussels, Belgium.
F P
FP
Duhoux
Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium.
I
I
Sinapi
Oncology-Hematology Services, Grand Hôpital de Charleroi, 6000, Charleroi, Belgium.
J L
JL
Canon
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001530:Belgium; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D000068878:Trastuzumab / Q000009:adverse effects*; D015275:Tumor Lysis Syndrome / Q000150:complications*
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C485206:pertuzumab; D000068878:Trastuzumab
Pertuzumab; Solid tumor; Trastuzumab; Tumor lysis syndrome